Clinical Trial Update: A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 3]

View source ↗

Summary

Clinical trial update for a Phase 3 study evaluating Afimkibart (RO7790121) as induction and maintenance therapy in adults with moderately to severely active ul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Afimkibart (RO7790121)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Moderately to Severely Active Ulcerative Colitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING